Editas Medicine Inc (NASDAQ:EDIT) shot up 11.7% during trading on Tuesday . The company traded as high as $34.81 and last traded at $34.32. 2,147,090 shares changed hands during trading, an increase of 124% from the average session volume of 956,945 shares. The stock had previously closed at $30.73.
A number of research firms have commented on EDIT. Barclays began coverage on Editas Medicine in a report on Wednesday, September 6th. They set an “overweight” rating and a $28.00 price target on the stock. Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. BidaskClub cut Editas Medicine from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. ValuEngine cut Editas Medicine from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research cut Editas Medicine from a “buy” rating to a “hold” rating in a report on Monday, November 13th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $26.73.
The firm has a market capitalization of $1,512.82, a PE ratio of -10.29 and a beta of 4.94. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12.
In other news, CFO Andrew A. F. Hack sold 14,649 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $24.68, for a total transaction of $361,537.32. Following the completion of the transaction, the chief financial officer now owns 5,000 shares in the company, valued at $123,400. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew A. F. Hack sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $25.35, for a total value of $126,750.00. Following the transaction, the chief financial officer now owns 5,000 shares of the company’s stock, valued at approximately $126,750. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,315 shares of company stock valued at $1,177,370. Company insiders own 19.40% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP purchased a new position in Editas Medicine in the third quarter worth about $667,000. Granahan Investment Management Inc. MA grew its position in Editas Medicine by 7.1% in the third quarter. Granahan Investment Management Inc. MA now owns 241,719 shares of the company’s stock worth $5,804,000 after acquiring an additional 15,999 shares in the last quarter. Allianz Asset Management GmbH purchased a new position in Editas Medicine in the third quarter worth about $3,263,000. Schwab Charles Investment Management Inc. grew its position in Editas Medicine by 18.6% in the third quarter. Schwab Charles Investment Management Inc. now owns 117,012 shares of the company’s stock worth $2,810,000 after acquiring an additional 18,366 shares in the last quarter. Finally, Greenwoods Asset Management Ltd grew its position in Editas Medicine by 156.3% in the third quarter. Greenwoods Asset Management Ltd now owns 182,000 shares of the company’s stock worth $4,370,000 after acquiring an additional 111,000 shares in the last quarter. Institutional investors own 65.70% of the company’s stock.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.